Daxas
NICE recommends AstraZeneca lung treatment
July 3, 2017Sales and Marketing AstraZeneca, Daxas, NICE
AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) it has emerged, …
NICE turns down AZ’s chronic obstructive pulmonary disease drug
February 13, 2017Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …
Boehringer’s COPD drug passes hurdle
May 23, 2012Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol
Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial. The manufacturer wants the …
NICE rejects Merck’s COPD drug Daxas
December 9, 2011Sales and Marketing COPD, Daxas, Merck, Nycomed
NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …
Merck’s COPD drug rejected by NICE
September 15, 2011Sales and Marketing Daxas, MSD, Merck & Co, NICE, roflumilast
NICE has not recommended Merck Co’s Daxas and has advised the firm to conduct a clinical trial in order to …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Nycomed’s Q3 undermined by pantoprazole decline
November 11, 2010Sales and Marketing Daxas, Guangdong Techpool Bio-Pharma, Nycomed, Protium, pantoprazole
Nycomed has seen its sales inch downwards in the third quarter, as the decline of its biggest seller pantoprazole continued. …
New COPD and asthma treatments jostle for market space
October 6, 2010Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma
Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …
Nycomed partners with Merck on Daxas
April 26, 2010Sales and Marketing Daxas, Merck & Co, Nycomed
Swiss firm Nycomed and Merck & Co have agreed to co-promote oral chronic obstructive pulmonary disease candidate Daxas in Europe. …
Nycomed earmarks $96m for Russian manufacturing
September 24, 2009Manufacturing and Production Daxas, Nycomed, Russia
Swiss drugmaker Nycomed has provided more details of its plan to build a large-scale production facility in Russia.In July, Nycomed …
Pfizer pulls out of Daxas collaboration
July 7, 2005Sales and Marketing Daxas, Nycomed, Pfizer
Pfizer has pulled out of an agreement with Altana Pharma to develop and market a new treatment for asthma and …
Latest content
Five Facts about cardiovascular disease
